Small-molecule inhibitors, neutralizing antibodies, and glycan mimetics that interfere with Gal-1 lattice formation are currently being investigated as adjuvant therapeutic strategies aimed at restoring antitumor immunity, inhibiting angiogenesis, and restricting tumor dissemination [64]. The gene discussed is LGALS1; the disease is neoplasm.